Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Physiologically based pharmacokinetic modeling [[electronic resource] ] : science and applications / / edited by Micaela B. Reddy ... [et al.]
| Physiologically based pharmacokinetic modeling [[electronic resource] ] : science and applications / / edited by Micaela B. Reddy ... [et al.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2005 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina |
615.7040724
615/.7 |
| Altri autori (Persone) | ReddyMicaela B |
| Soggetto topico |
Pharmacokinetics
Xenobiotics Toxicology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-27583-9
9786610275830 0-470-24616-2 0-471-47876-8 0-471-47877-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS; 1.1 Introduction; 1.2 A Historical Perspective; 1.2.1 Responses to Inhaled Compounds; 1.2.2 Pharmaceutical Applications; 1.2.3 Occupational and Environmental Applications; 1.2.4 Digital Computation and PBPK Modeling; 1.3 Expansion of PBPK Model Applications; 1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data; 1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors
1.3.3 Chemicals as Probes of Biological Processes1.3.4 Risk Assessment Applications; 1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response; 1.4 Summary; Notation; References; PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS; CHAPTER 2 HALOGENATED ALKANES; 2.1 Introduction; 2.2 PBPK Model Development for Volatile Organics; 2.2.1 Model Formulation; 2.2.2 Model Equations; 2.2.3 Model Parameterization; 2.2.4 Model Calculations; 2.3 Experimental Methods Demonstrated for Groups of Chemicals; 2.4 PBPK Models for Halogenated Alkanes; 2.4.1 Anesthetic Gases 2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons2.4.3 Halogenated Alkanes; 2.5 Summary; Notation; References; CHAPTER 3 HALOGENATED ALKENES; 3.1 Introduction; 3.2 The Chloroethylenes: Background; 3.3 Review of PBPK Models; 3.3.1 Vinyl Chloride (VC); 3.3.2 Vinyl Fluoride (VF); 3.3.3 cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE); 3.3.4 Vinylidene Chloride (VDC); 3.3.5 Trichloroethylene (TCE); 3.3.6 Tetrachloroethylene (PERC); 3.3.7 Allyl Chloride (AC); 3.3.8 b-Chloroprene (CD); 3.3.9 Hexachlorobutadiene, HCB; 3.4 Summary; Notation; References CHAPTER 4 ALKENE AND AROMATIC COMPOUNDS4.1 Introduction; 4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds; 4.2.1 Metabolism and Mode of Action; 4.2.2 Model Structures; 4.2.3 PK Differences; 4.2.4 Extrahepatic Metabolism and Transport of Metabolites; 4.2.5 GSH Conjugation; 4.2.6 Endogenous Production; 4.2.7 Reactivity with DNA and Protein; 4.2.8 Inhibition of Second Oxidative Steps; 4.2.9 Variability and PK Differences; 4.2.10 Subcompartments in PBPK Models; 4.2.11 "Privileged Access" of Epoxide Hydratase to Epoxide Substrates 4.3 Review of Aromatic and Alkene PBPK Models4.3.1 Benzene-A Known Human Carcinogen with an Uncertain Mode of Action; 4.3.2 Styrene-Early PBPK Models; 4.3.3 1,3-Butadiene; 4.3.4 Isoprene; 4.3.5 Ethylene, Propylene, and Their Oxides; 4.3.6 Naphthalene and Other PAHs; 4.3.7 Halobenzenes; 4.3.8 Miscellaneous Related Compounds; 4.4 Summary; Notation; References; CHAPTER 5 REACTIVE VAPORS IN THE NASAL CAVITY; 5.1 Introduction; 5.1.1 Nasal Effects and Risk Assessment; 5.1.2 General Models for Nasal Uptake; 5.2 No Air-Phase Models; 5.2.1 The "Perfused Nose" Model; 5.2.2 Vinyl Acetate 5.3 Creating the Air-Phase Compartments |
| Record Nr. | UNINA-9910143555503321 |
| Hoboken, N.J., : Wiley-Interscience, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Physiologically based pharmacokinetic modeling [[electronic resource] ] : science and applications / / edited by Micaela B. Reddy ... [et al.]
| Physiologically based pharmacokinetic modeling [[electronic resource] ] : science and applications / / edited by Micaela B. Reddy ... [et al.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2005 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina |
615.7040724
615/.7 |
| Altri autori (Persone) | ReddyMicaela B |
| Soggetto topico |
Pharmacokinetics
Xenobiotics Toxicology |
| ISBN |
1-280-27583-9
9786610275830 0-470-24616-2 0-471-47876-8 0-471-47877-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS; 1.1 Introduction; 1.2 A Historical Perspective; 1.2.1 Responses to Inhaled Compounds; 1.2.2 Pharmaceutical Applications; 1.2.3 Occupational and Environmental Applications; 1.2.4 Digital Computation and PBPK Modeling; 1.3 Expansion of PBPK Model Applications; 1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data; 1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors
1.3.3 Chemicals as Probes of Biological Processes1.3.4 Risk Assessment Applications; 1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response; 1.4 Summary; Notation; References; PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS; CHAPTER 2 HALOGENATED ALKANES; 2.1 Introduction; 2.2 PBPK Model Development for Volatile Organics; 2.2.1 Model Formulation; 2.2.2 Model Equations; 2.2.3 Model Parameterization; 2.2.4 Model Calculations; 2.3 Experimental Methods Demonstrated for Groups of Chemicals; 2.4 PBPK Models for Halogenated Alkanes; 2.4.1 Anesthetic Gases 2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons2.4.3 Halogenated Alkanes; 2.5 Summary; Notation; References; CHAPTER 3 HALOGENATED ALKENES; 3.1 Introduction; 3.2 The Chloroethylenes: Background; 3.3 Review of PBPK Models; 3.3.1 Vinyl Chloride (VC); 3.3.2 Vinyl Fluoride (VF); 3.3.3 cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE); 3.3.4 Vinylidene Chloride (VDC); 3.3.5 Trichloroethylene (TCE); 3.3.6 Tetrachloroethylene (PERC); 3.3.7 Allyl Chloride (AC); 3.3.8 b-Chloroprene (CD); 3.3.9 Hexachlorobutadiene, HCB; 3.4 Summary; Notation; References CHAPTER 4 ALKENE AND AROMATIC COMPOUNDS4.1 Introduction; 4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds; 4.2.1 Metabolism and Mode of Action; 4.2.2 Model Structures; 4.2.3 PK Differences; 4.2.4 Extrahepatic Metabolism and Transport of Metabolites; 4.2.5 GSH Conjugation; 4.2.6 Endogenous Production; 4.2.7 Reactivity with DNA and Protein; 4.2.8 Inhibition of Second Oxidative Steps; 4.2.9 Variability and PK Differences; 4.2.10 Subcompartments in PBPK Models; 4.2.11 "Privileged Access" of Epoxide Hydratase to Epoxide Substrates 4.3 Review of Aromatic and Alkene PBPK Models4.3.1 Benzene-A Known Human Carcinogen with an Uncertain Mode of Action; 4.3.2 Styrene-Early PBPK Models; 4.3.3 1,3-Butadiene; 4.3.4 Isoprene; 4.3.5 Ethylene, Propylene, and Their Oxides; 4.3.6 Naphthalene and Other PAHs; 4.3.7 Halobenzenes; 4.3.8 Miscellaneous Related Compounds; 4.4 Summary; Notation; References; CHAPTER 5 REACTIVE VAPORS IN THE NASAL CAVITY; 5.1 Introduction; 5.1.1 Nasal Effects and Risk Assessment; 5.1.2 General Models for Nasal Uptake; 5.2 No Air-Phase Models; 5.2.1 The "Perfused Nose" Model; 5.2.2 Vinyl Acetate 5.3 Creating the Air-Phase Compartments |
| Record Nr. | UNINA-9910830979003321 |
| Hoboken, N.J., : Wiley-Interscience, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Physiologically based pharmacokinetic modeling : science and applications / / edited by Micaela B. Reddy ... [et al.]
| Physiologically based pharmacokinetic modeling : science and applications / / edited by Micaela B. Reddy ... [et al.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2005 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina | 615/.7 |
| Altri autori (Persone) | ReddyMicaela B |
| Soggetto topico |
Pharmacokinetics
Xenobiotics Toxicology |
| ISBN |
1-280-27583-9
9786610275830 0-470-24616-2 0-471-47876-8 0-471-47877-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS; 1.1 Introduction; 1.2 A Historical Perspective; 1.2.1 Responses to Inhaled Compounds; 1.2.2 Pharmaceutical Applications; 1.2.3 Occupational and Environmental Applications; 1.2.4 Digital Computation and PBPK Modeling; 1.3 Expansion of PBPK Model Applications; 1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data; 1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors
1.3.3 Chemicals as Probes of Biological Processes1.3.4 Risk Assessment Applications; 1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response; 1.4 Summary; Notation; References; PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS; CHAPTER 2 HALOGENATED ALKANES; 2.1 Introduction; 2.2 PBPK Model Development for Volatile Organics; 2.2.1 Model Formulation; 2.2.2 Model Equations; 2.2.3 Model Parameterization; 2.2.4 Model Calculations; 2.3 Experimental Methods Demonstrated for Groups of Chemicals; 2.4 PBPK Models for Halogenated Alkanes; 2.4.1 Anesthetic Gases 2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons2.4.3 Halogenated Alkanes; 2.5 Summary; Notation; References; CHAPTER 3 HALOGENATED ALKENES; 3.1 Introduction; 3.2 The Chloroethylenes: Background; 3.3 Review of PBPK Models; 3.3.1 Vinyl Chloride (VC); 3.3.2 Vinyl Fluoride (VF); 3.3.3 cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE); 3.3.4 Vinylidene Chloride (VDC); 3.3.5 Trichloroethylene (TCE); 3.3.6 Tetrachloroethylene (PERC); 3.3.7 Allyl Chloride (AC); 3.3.8 b-Chloroprene (CD); 3.3.9 Hexachlorobutadiene, HCB; 3.4 Summary; Notation; References CHAPTER 4 ALKENE AND AROMATIC COMPOUNDS4.1 Introduction; 4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds; 4.2.1 Metabolism and Mode of Action; 4.2.2 Model Structures; 4.2.3 PK Differences; 4.2.4 Extrahepatic Metabolism and Transport of Metabolites; 4.2.5 GSH Conjugation; 4.2.6 Endogenous Production; 4.2.7 Reactivity with DNA and Protein; 4.2.8 Inhibition of Second Oxidative Steps; 4.2.9 Variability and PK Differences; 4.2.10 Subcompartments in PBPK Models; 4.2.11 "Privileged Access" of Epoxide Hydratase to Epoxide Substrates 4.3 Review of Aromatic and Alkene PBPK Models4.3.1 Benzene-A Known Human Carcinogen with an Uncertain Mode of Action; 4.3.2 Styrene-Early PBPK Models; 4.3.3 1,3-Butadiene; 4.3.4 Isoprene; 4.3.5 Ethylene, Propylene, and Their Oxides; 4.3.6 Naphthalene and Other PAHs; 4.3.7 Halobenzenes; 4.3.8 Miscellaneous Related Compounds; 4.4 Summary; Notation; References; CHAPTER 5 REACTIVE VAPORS IN THE NASAL CAVITY; 5.1 Introduction; 5.1.1 Nasal Effects and Risk Assessment; 5.1.2 General Models for Nasal Uptake; 5.2 No Air-Phase Models; 5.2.1 The "Perfused Nose" Model; 5.2.2 Vinyl Acetate 5.3 Creating the Air-Phase Compartments |
| Record Nr. | UNINA-9910877640203321 |
| Hoboken, N.J., : Wiley-Interscience, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||